Leticia Toledo‐Sherman

The promise and peril of chemical probes

C.H. Arrowsmith, James E. Audia, Christopher P. Austin et al. · Nature Chemical Biology · 2015 · 836 citations · Full text

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease

Michael E. Prime, Ole A. Andersen, John J. Barker et al. · Journal of Medicinal Chemistry · 2012 · 69 citations · Full text

Structure–activity Relationship, Biochemistry, G Protein-coupled Receptor +12

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Leticia Toledo‐Sherman, Michael E. Prime, Ladislav Mrzljak et al. · Journal of Medicinal Chemistry · 2015 · 61 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Neurodegenerative Diseases +15

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease

Vahri Beaumont, Ladislav Mrzljak, Ulrike Dijkman et al. · Experimental Neurology · 2016 · 55 citations

Electrophysiological Alterations, Molecular Physiology, Molecular Biology +6

Emerging β-Sheet Rich Conformations in Supercompact Huntingtin Exon-1 Mutant Structures

Hongsuk Kang, Francisco X. Vázquez, Leili Zhang et al. · Journal of the American Chemical Society · 2017 · 54 citations

Age Onset, Protein Assembly, Huntingtin Protein +21